The family B1 GPCR: Structural aspects and interaction with accessory proteins

Current Drug Targets

Volumn 13, Issue 1, 2012, Pages 103-115

  Couvineau, Alain ^a,b   Laburthe, Marc ^a,b  

^a CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Accessory proteins; Calcitonin; Cell signaling; Class B GPCR; CRF; CTR; Family B1 GPCR; GCCR; GIP; GLP 1; GLP 2; Glucagon; GPCR; GRF; Hormone; Neuropeptide; PAC1; PDZ; Photolabeling; PTH; PTH1R; PTH2R; RAMP; Receptor; Secretin; Structure; Tyrosine based motif; VIP; VPAC1; VPAC2

Indexed keywords

ADENYLATE CYCLASE; CALCITONIN; CALCITONIN RECEPTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR; CYCLIC AMP; G PROTEIN COUPLED RECEPTOR; GASTRIC INHIBITORY PEPTIDE RECEPTOR; GLUCAGON; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 2 RECEPTOR; GLUCAGON RECEPTOR; GROWTH HORMONE RELEASING FACTOR RECEPTOR; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; LIGAND; METABOTROPIC RECEPTOR; PARATHYROID HORMONE RECEPTOR; PITUITARY ADENYLYL CYCLASE ACTIVATING PEPTIDE RECEPTOR 1; PROTEIN 14 3 3; RECEPTOR PROTEIN; RHODOPSIN; SECRETIN; SECRETIN RECEPTOR; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

AMINO TERMINAL SEQUENCE; BETA SHEET; CHRONIC INFLAMMATION; DIABETES MELLITUS; DISULFIDE BOND; GENE EXPRESSION; HUMAN; MOLECULAR RECOGNITION; MOLECULAR STABILITY; NERVE DEGENERATION; NONHUMAN; OSTEOPOROSIS; PROTEIN FAMILY; PROTEIN FOLDING; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; STRESS;

ANIMALS; HUMANS; PROTEIN BINDING; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, GASTROINTESTINAL HORMONE; SECRETIN; SIGNAL TRANSDUCTION; X-RAY DIFFRACTION;

EID: 84855822647     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012798868434     Document Type: Review

References (109)

1. Fredrikson R, Schiöth B. G Protein-coupled receptors in human genome. In: Rognan, D. (Ed), Ligand Design for G Protein-coupled receptors. Wiley-VCH, Weinheim, 2006; vol. 30, pp.1-27.
2. Millar RP, Newton CL. The year in G protein-coupled receptor research. Mol Endocrinol 2010; 24: 261-74.
3. Jalink K, Moolenaar WH. G protein-coupled receptors: the inside story. BioEssays 2010; 32: 13-6.
4. Lagerström MC, Schiöth HB. Structural diversity of G-protein coupled receptors and significance for drug discovery. Nat Rev Drug Discov 2008; 7: 339-58.
5. Palczewski K, Kumasaka T, Hori T, et al. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 2000; 289: 739-45.
6. Warne T, Serrano-Vega MJ, Baker JG, et al. Structure of a beta1-adrenergic G-protein-coupled receptor. Nature 2008; 454: 486-91.
7. Cherezov V, Rosenbaum DM, Hanson MA, et al. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 2007; 318: 1258-65.
8. Jaakola VP, Griffith MT, Hanson MA, et al. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 2008; 322: 1211-17.
9. Murakami M, Kouyama T. Crystal structure of squid rhodopsin. Nature 2008; 453: 363-7.
10. Scheerer P, Park JH, Hildebrand PW, et al. Crystal structure of opsin in its G-protein-interacting conformation. Nature 2008; 455: 497-502.
11. Chien EY, Liu W, Zhao Q, et al. Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science 2010; 330: 1091-5.
12. Wu B, Chien EY, Mol CD, et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 2010; 330: 1066-71.
13. Woehler A, Ponimaskin EG. G protein-Mediated signaling: same receptor, multiple effectors. Curr Mol Pharmacol 2009; 2: 237-48.
14. Brady AE, Limbird LE. G protein-coupled receptor interacting proteins: emerging role in localization and signal transduction. Cell Signal 2002; 14: 297-309.
15. Bockaert J, Fagni L, Dumuis A, Marin P. GPCR interacting proteins (GIP) Pharmacol. Therapeuth 2004; 103: 203-21.
16. Laburthe M, Couvineau A, Tan V. Class II G protein-coupled receptors for VIP and PACAP: structure, models of activation and pharmacology. Peptides 2007; 28: 1631-39.
17. Laburthe M, Couvineau A, Marie JC. VPAC receptors for VIP and PACAP. Receptors Channels 2002; 8: 137-53.
18. Couvineau A, Ceraudo E, Tan YV, Laburthe M. VPAC1 receptor binding site: contribution of photoaffinity labeling approach. Neuropeptides 2010; 44: 127-32.
19. Laburthe M, Couvineau A, Gaudin P, Maoret JJ, Rouyer-Fessard C, Nicole P. Receptors for VIP, PACAP, secretin, GRF, glucagon, GLP-1, and other members of their new family of G protein-linked receptors: structure-function relationship with special reference to the human VIP-1 receptor. Ann N Y Acad Sci 1996; 805: 94-109.
20. Neumann JM, Couvineau A, Murail S, Lacapère JJ, Jamin N, Laburthe M. Class-B GPCR activation: is ligand helix-capping the key? Trends Biochem Sci 2008; 33: 314-19.
21. Delgado M, Pozo D, Ganea D. The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol Rev 2004; 56: 249-90.
22. Gozes I, Divinsky I, Pilzer I, Fridkin M, Brenneman DE, Spier AD. From vasoactive intestinal peptide (VIP) through activitydependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and celldivision. J Mol Neurosci 2003; 20: 315-22.
23. Vaudry D, Falluel-Morel A, Bourgault S, et al. Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev 2009; 61: 283-357.
24. Campbell RM, Bongers J, Felix AM. Rational design, synthesis, and biological evaluation of novel growth hormone releasing factor analogues. Biopolymers 1995; 37: 67-88.
25. Inzucchi SE, McGuire DK. New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond. Circulation 2008; 117: 574-84.
26. Brubaker PL. Incretin-based therapies: mimetics versus protease inhibitors. Trends Endocrinol Metab 2007; 18: 240-45.
27. Jeppesen PB. Glucagon-like peptide-2: update of the recent clinical trials. Gastroenterology 2006; 130: S127-31.
28. Epstein S. Is cortical bone hip? What determines cortical bone properties? Bone 2007; 41: S3-8.
29. Mulder JE, Kolatkar NS, LeBoff MS. Drug insight: existing and emerging therapies for osteoporosis. Nat Clin Pract Endocrinol Metab 2006; 2: 670-80.
30. Gilligan PJ, Li YW. Corticotropin-releasing factor antagonists: recent advances and exciting prospects for the treatment of human diseases. Curr Opin Drug Discov Devel 2004; 7: 487-97.
31. Chapter MC, White CM, DeRidder A, Chadwick W, Martin B, Maudsley S. Chemicalmodification of class II G protein-coupled receptor ligands: frontiers in the development of peptide analogs as neuroendocrine pharmacological therapies. Pharmacol Ther 2010; 125: 39-54.
32. Beebe X, Darczak D, Davis-Taber RA, et al. Discovery and SAR of hydrazide antagonists of the pituitary adenylate cyclaseactivating polypeptide (PACAP) receptor type 1 (PAC1-R). Bioorg Med Chem Lett 2008; 18: 2162-6.
33. Chu A, Caldwell JS, Chen YA. Identification and characterization of a small molecule antagonist of human VPAC(2) receptor. Mol Pharmacol 2010; 77: 95-101.
34. Ling A, Hong Y, Gonzalez J, et al. Identification of alkylidene hydrazides as glucagon receptor antagonists. J Med Chem 2001; 44: 3141-9.
35. Salvatore CA, Mallee JJ, Bell IM, et al. Identification and pharmacological characterization of domains involved in binding of CGRP receptor antagonists to the calcitonin-like receptor. Biochemistry 2006; 45: 1881-7.
36. McDonald IM, Austin C, Buck IM, et al. Discovery and characterization of novel, potent, non-peptide parathyroid hormone-1 receptor antagonists. J Med Chem 2007; 50: 4789-92.
37. Zorrilla EP, Koob GF. Progress in corticotropin-releasing factor-1 antagonist development. Drug Discov Today 2010; 15: 371-83.
38. Hoare SR. Allosteric modulators of class B G-protein-coupled receptors. Curr. Neuropharmacol 2007; 5: 168-79.
39. Rickard DJ, Wang FL, Rodriguez-Rojas AM, et al. Intermittent treatment with parathyroid hormone (PTH) as well as a non-peptide small molecule agonist of the PTH1 receptor inhibits adipocyte differentiation in human bone marrow stromal cells. Bone 2006; 39: 1361-72.
40. Grace CR, Perrin MH, DiGruccio MR, et al. NMR structure and peptide hormone binding site of the first extracellular domain of a type B1 G protein-coupled receptor. Proc Natl Acad Sci U S A 2004; 101: 12836-41.
41. Sun C, Song D, Davis-Taber RA, et al. Solution structure and mutational analysis of pituitary adenylate cyclase-activating polypeptide binding to the extracellular domain of PAC1-RS. Proc Natl Acad Sci U S A 2007; 104: 7875-80.
42. Pioszak AA, Xu HE. Molecular recognition of parathyroid hormone by its G protein-coupled receptor. Proc Natl Acad Sci U S A 2008; 105: 5034-39.
43. Runge S, Thøgersen H, Madsen K, Lau J, Rudolph R. Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain. J Biol Chem 2008; 283: 11340-47.
44. Parthier C, Kleinschmidt M, Neumann P, et al. Crystal structure of the incretin-bound extracellular domain of a G protein-coupled receptor. Proc Natl Acad Sci U S A 2007; 104: 13942-47.
45. Pioszak AA, Parker NR, Suino-Powell K, Xu HE. Molecular recognition of corticotropin-releasing factor by its G-proteincoupled receptor CRFR1. J Biol Chem 2008; 283: 32900-12.
46. Parthier C, Reedtz-Runge S, Rudolph R, Stubbs MT. Passing the baton in class B GPCRs: peptide hormone activation via helix induction? Trends Biochem. Sci. 2009; 34: 303-10.
47. Couvineau A, Rouyer-Fessard C, Laburthe M. Presence of a Nterminal signal peptide in class II G protein-coupled receptors: crucial role for expression of the human VPAC1 receptor. Regul Pept 2004; 123: 181-5.
48. Couvineau A, Fabre C, Gaudin P, Maoret JJ, Laburthe M. Mutagenesis of N-glycosylation sites in the human vasoactive intestinal peptide 1 receptor. Evidence that asparagine 58 or 69 is crucial for correct delivery of the receptor to plasma membrane. Biochemistry 1996; 35:1745-52.
49. Hoare SRJ. Mechanism of peptide and nonpeptide ligand binding to class B G-protein-coupled receptors. DDT 2005; 10: 417-27.
50. Braun, W, Wider G, Lee KH, Wüthrich K. Conformation of glucagon in a lipid-water inter-phase by proton nuclear magnetic resonance. J Mol Biol 1983; 169: 921-48.
51. Gronenborn, AM, Bovermann G, Clore GM. A 1H-NMR study of the solution conformation of secretin. FEBS Lett 1987; 215: 88-94.
52. Romier C, Bernassau JM, Cambillau C, Darbon H. Solution structure of human corticotropin releasing factor by 1H-NMR and distance geometry with restrained molecular dynamics. Protein Eng 1993; 6: 149-56.
53. Thornton K, Gorenstein DG. Structure of glucagon-like peptide (7-36) amide in a dodecylphosphocholine micelle as determined by 2D NMR. Biochemistry 1994; 33: 3532-9.
54. Pelligrini M, Royo M, Rosenblatt M, Chorev M, Mierke DF. Addressing the tertiary structure of human parathyroid hormone-(1-34). J Biol Chem 1998; 273: 10420-7.
55. Inooka H, Ohtaki T, Kitahara O, et al. Conformation of a peptide ligand bound to its G-protein coupled receptor. Nat Struct Biol 2001; 8: 161-5.
56. Tan YV, Couvineau A, Van Rampelbergh J, Laburthe M. Photoaffinity labeling demonstrates physical contact between vasoactive intestinal peptide and the N-terminal ectodomain of the human VPAC1 receptor. J Biol Chem 2003; 278: 36531-6.
57. 6]-VIP. J Biol Chem 2004; 279: 38889-94.
58. Tan YV, Couvineau A, Murail S, et al. Peptide agonist docking in the N-terminal ectodomain of a class II G protein-coupled receptor, the VPAC1 receptor. Photoaffinity, NMR, and molecular modeling. J Biol Chem 2006; 281: 12792-8.
59. Ceraudo E, Murail S, Tan YV, et al. The vasoactive intestinal peptide (VIP) alpha-Helix up to C terminus interacts with the Nterminal ectodomain of the human VIP/Pituitary adenylate cyclaseactivating peptide 1 receptor: photoaffinity, molecular modeling, and dynamics. Mol Endocrinol 2008; 22: 147-55.
60. Martin B, Lopez de Maturana R, Brenneman R, Walent T, Mattson MP, Maudsley S. Class II G protein-coupled receptors and their ligands in neuronal function and protection. Neuromolecular Med 2005; 7: 3-36.
61. Guo J, Iida-Klein A, Huang X, Abou-Samra AB, Segre GV, Bringhurst FR. Parathyroid hormone (PTH)/PTH-related peptide receptor density modulates activation of phospholipase C and phosphate transport by PTH in LLC-PK1 cells. Endocrinology 1995; 136: 3884-91.
62. Ritter SL, Hall RA. Fine-tuning of GPCR activity by receptorinteracting proteins. Nat Rev Mol Cell Biol 2009; 10: 819-30.
63. Brzostowski JA, Kimmel AR. Signaling at zero G: G-proteinindependent functions for 7-TM receptors. Trends Biochem Sci 2001; 26: 291-7.
64. Daulat AM, Maurice P, Jockers R. Recent methodological advances in the discovery of GPCR-associated protein complexes. Trends Pharmacol Sci 2009; 30: 72-8.
65. Sexton PM, Poyner DR, Simms J, Christopoulos A, Hay DL. Modulating receptor function through RAMPs: can they represent drug targets in themselves? Drug Discov Today 2009; 14: 413-9.
66. McLatchie LM, Fraser NJ, Main MJ, et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 1998; 393: 333-9.
67. Parameswaran N, Spielman WS. RAMPs: The past, present and future. Trends Biochem Sci 2006; 31: 631-8.
68. Bomberger JM, Parameswaran N, Hall CS, Aiyar N, Spielman WS. Novel function for receptor activity-modifying proteins (RAMPs) in post-endocytic receptor trafficking. J Biol Chem 2005; 280: 9297-307.
69. Doods H, Arndt K, Rudolf K, Just S. CGRP antagonists: unravelling the role of CGRP in migraine. Trends Pharmacol Sci 2007; 28: 580-7.
70. Hay DL, Christopoulos G, Christopoulos A, Sexton PM. Determinants of 1-piperidinecarboxamide, N-[2-[5-amino-l-[4-(4-pyridinyl)-l piperazinyl]carbonyl]pentyl]amino]-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl) (BIBN4096BS) affinity for calcitonin gene-related peptide and amylin receptors--the role of receptor activity modifying protein 1. Mol Pharmacol 2006; 70: 1984-91.
71. Salvatore CA, Mallee JJ, Bell IM, et al. Identification and pharmacological characterization of domains involved in binding of CGRP receptor antagonists to the calcitonin-like receptor. Biochemistry 2006; 45: 1881-7.
72. Mahon MJ, Shimada M. Calmodulin interacts with the cytoplasmic tails of the parathyroid hormone 1 receptor and a sub-set of class b G-protein coupled receptors. FEBS Lett 2005; 579: 803-7.
73. Bretscher A, Edwards K, Fehon RG. ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol 2002; 3: 586-99.
74. Kurakin A, Swistowski A, Wu SC, Bredesen DE. The PDZ domain as a complex adaptive system. PLoS One 2007; 2: e953.
75. Beuming T, Skrabanek L, Niv MY, Mukherjee P, Weinstein H. PDZBase: a protein-protein interaction database for PDZ-domains. Bioinformatics 2005; 21: 827-8.
76. Songyang Z, Fanning AS, Fu C, et al. Recognition of unique carboxyl-terminal motifs by distinct PDZ domains. Science 1997; 275: 73-7.
77. Mahon MJ, Donowitz M, Yun CC, Segre GV. Na(+)/H(+) exchanger regulatory factor 2 directs parathyroid hormone 1 receptor signalling. Nature 2002; 417: 858-61.
78. Mahon MJ, Segre GV. Stimulation by parathyroid hormone of a NHERF-1 assembled complex consisting of the parathyroid hormone I receptor, phospholipase Cbeta and actin increases intracellular calcium in opossum kidney cells. J Biol Chem 2004; 279: 23550-8.
79. Rochdi MD, Watier V, La Madeleine C, Nakata H, Kozasa T, Parent JL. Regulation of GTP-binding protein alpha q (Galpha q) signaling by the ezrin-radixin-moesin-binding phosphoprotein-50 (EBP50). J Biol Chem 2002; 277: 40751-9.
80. Fam SR, Paquet M, Castleberry AM, et al. P2Y1 receptor signaling is controlled by interaction with the PDZ scaffold NHERF-2. Proc Natl Acad Sci U S A 2005; 102: 8042-7.
81. Lee-Kwon W, Kim JH, Choi JW, et al. Ca2+-dependent inhibition of NHE3 requires PKC alpha which binds to E3KARP to decrease surface NHE3 containing plasma membrane complexes. Am J Physiol Cell Physiol 2003; 285: C1527-36.
82. Wang B, Bisello A, Yang Y, Romero GG, Friedman PA. NHERF1 regulates parathyroid hormone receptor membrane retention without affecting recycling. J Biol Chem 2007; 282: 36214-22.
83. Wang B, Yang Y, Abou-Samra AB, Friedman PA. NHERF1 regulates parathyroid hormone receptor desensitization: interference with beta-arrestin binding. Mol Pharmacol 2009; 75: 1189-97.
84. Wang B, Yang Y, Friedman PA. Na/H exchange regulatory factor 1, a novel AKT-associating protein, regulates extracellular signalregulated kinase signaling through a B-Raf-mediated pathway. Mol Biol Cell 2008; 19: 1637-45.
85. Saito M, Sugai M, Katsushima Y, Yanagisawa T, Sukegawa J, Nakahata N. Increase in cell-surface localization of parathyroid hormone receptor by cytoskeletal protein 4.1G. Biochem J 2005; 392: 75-81.
86. Tazawa H, Takahashi S, Zilliacus J. Interaction of the parathyroid hormone receptor with the 14-3-3 protein. Biochim Biophys Acta 2003; 1620: 32-8.
87. Sugai M, Saito M, Sukegawa I, et al. PTH/PTH-related protein receptor interacts directly with Tctex-1 through its COOH terminus. Biochem Biophys Res Commun 2003; 311: 24-31.
88. Christopoulos A, Christopoulos G, Morfis M, et al. Novel receptor partners and function of receptor activity-modifying proteins. J Biol Chem 2002; 278: 3293-97.
89. Gee HY, Kim YW, Jo MJ, et al. Synaptic scaffolding molecule binds to and regulates vasoactive intestinal polypeptide type-1 receptor in epithelial cells. Gastroenterology 2009; 137: 607-17.
90. Sheng M, Sala C. PDZ domains and the organization of supramolecular complexes. Annu Rev Neurosci 2001; 24: 1-29.
91. Daëron M, Jaeger S, Du Pasquier L, Vivier E. Immunoreceptor tyrosine-based inhibition motifs: a quest in the past and future. Immunol Rev 2008; 224: 11-43.
92. El Firar A, Voisin T, Rouyer-Fessard C, Ostuni MA, Couvineau A, Laburthe M. Discovery of a functional immunoreceptor tyrosinebased switch motif in a 7-transmembrane-spanning receptor: role in the orexin receptor OX1R-driven apoptosis. FASEB J 2009; 23: 4069-80.
93. Ferjoux G, Lopez F, Esteve JP, et al. Critical role of Src and SHP-2 in sst2 somatostatin receptor-mediated activation of SHP-1 and inhibition of cell proliferation. Mol Biol Cell 2003; 14: 3911-28.
94. Duchene J, Schanstra JP, Pecher C, et al. A novel protein-protein interaction between a G protein coupled receptor and the phosphatase SHP-2 is involved in bradykinin induced inhibition of cell proliferation. J Biol Chem 2002; 277: 40375-83.
95. Vatinel S, Ferrand A, Lopez F, et al. An ITIM-like motif within the CCK2 receptor sequence required for interaction with SHP-2 and the activation of the AKT pathway. Biochim Biophys Acta 2006; 1763: 1098-107.
96. Rouet-Benzineb P, Rouyer-Fessard C, Jarry A, et al. Orexins acting at native OX(1) receptor in colon cancer and neuroblastoma cells or at recombinant OX(1) receptor suppress cell growth by inducing apoptosis. J Biol Chem 2004; 279: 45875-86.
97. Voisin T, El Firar A, Rouyer-Fessard C, Gratio V, Laburthe M. A hallmark of immunoreceptor, the tyrosine-based inhibitory motif ITIM, is present in the G protein-coupled receptor OX1R for orexins and drives apoptosis: a novel mechanism. FASEB J 2008; 22: 1993-2002.
98. Laburthe M, Voisin T, El Firar A. Orexins/hypocretins and orexin receptors in apoptosis: a mini-review. Acta Physiol (Oxf) 2010; 198: 393-402.
99. Vacic V, McCarthy S, Malhotra D, et al. Duplications of the neuropeptide receptor gene VIPR2 confer significant risk for schizophrenia. Nature 2011(in press).
100. Lam IP, Siu FK, Chu JY, Chow BK. Multiple actions of secretin in the human body. Int Rev Cytol 2008; 265: 159-90.
101. Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 2008; 60: 470-512.
102. Drozdowski L, Thomson AB. Intestinal hormones and growth factors: effects on the small intestine. World J Gastroenterol 2009; 15: 385-406.
103. Gensure RC, Gardella TJ, Jüppner H. Parathyroid hormone and parathyroid hormone-related peptide, and their receptors. Biochem Biophys Res Commun 2005; 328: 666-78.
104. Naot D, Cornish J. The role of peptides and receptors of the calcitonin family in the regulation of bone metabolism. Bone 2008; 43: 813-8.
105. Perrin MH, Vale WW. Corticotropin releasing factor receptors and their ligand family. Ann N Y Acad Sci 1999; 885: 312-28.
106. Trimble ER, Bruzzone R, Biden TJ, Meehan CJ, Andreu D, Merrifield RB. Secretin stimulates cyclic AMP and inositol trisphosphate production in rat pancreatic acinar tissue by two fully independent mechanisms. Proc Natl Acad Sci USA 1987; 84: 3146-50.
107. Pombo CM, Zalvide J, Gaylinn BD, Diéguez C. Growth hormonereleasing hormone stimulates mitogen-activated protein kinase. Endocrinology 2000; 141: 2113-9.
108. Ahrén B. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nat Rev Drug Discov 2009; 8: 369-85.
109. Arzt E, Holsboer F. CRF signaling: molecular specificity for drug targeting in the CNS. Trends Pharmacol Sci 2006; 27: 531-8.